Greater Boston
A lot valuable scientific discoveries do not reach patients or markets, as the path from discovery to deal is difficult and hard to navigate. I help turn frontier biomedical science into companies, partnerships, and capital by structuring the IP, alliances, and cross-institutional deals that make it happen. As Director of Strategic Alliances at the Broad Institute, I'm the BD lead for a large part of the institute's research portfolio, spanning oncology, neuropsychiatry, spatial genomics, single-cell biology, cancer diagnostics, and data/computational platforms. The work ranges from shaping new company architectures and IP strategy for faculty ventures, to managing flagship pharma alliances, to designing multi-party consortium governance, to building frameworks for how research institutions partner around data and AI/ML assets. Over 13+ years in translational business development across four institutions, I've had BD ownership of 400+ assets, led or supported 20+ company formations (collectively raising $500M+ in follow-on funding), and structured $1B+ in aggregate partnership value. I've hired built BD teams at three institutions, managed portfolios spanning discovery through clinical stage, and worked across deal types including licensing, sponsored research, company formation, in-licensing, alliance management, and consortium design. Before the Broad, I built and ran a 25-person global innovation unit at Merck KGaA, and held BD leadership roles at Weill Cornell Medicine and UCLA. I'm a PhD neuroscientist (Rockefeller) with a postdoc in chemical and systems biology (Stanford) and an MSci in chemistry from Cambridge. My recent focus has been on how AI and computational tools are changing the assets research institutions produce and the partnership models needed around them. I've been leading our engagement with frontier AI companies around agentic interfaces to foundational research datasets, and developing frameworks for how institutions should value and structure partnerships around data, algorithms, and AI-enabled platforms.
BD lead for a significant portion of the Broad's scientific leadership across cancer biology, neuropsychiatry, spatial genomics, single-cell biology, diagnostics, and computational platforms. Active portfolio of 30+ concurrent deals in negotiation, cultivation, and alliance management. Company formation and portfolio company support: Shape company scope, IP architecture, and investor positioning for faculty ventures. Supported formation of 10+ companies at Broad with $200M+ in follow-on funding, spanning RNA therapeutics, spatial transcriptomics, liquid biopsy diagnostics, and circular mRNA. Support portfolio companies from formation through downstream partnering, including sublicensing and acquisition. Strategic alliances: BD lead on flagship partnerships. Guide governance, negotiate scope expansions, and manage long-horizon pharma relationships. Expansion of consortia by adding on new members. Data, AI, and novel asset partnerships: Developed and presented institutional frameworks for how the Broad values and structures partnerships around datasets, computational platforms, and AI/ML assets. Led strategic engagements with frontier AI companies.Initiated data licensing conversations with multiple AI/ML companies. Translational strategy: Contributed to the design and strategic rationale for an institutional translational venture platform, working closely with the CBO on model architecture and positioning. Cross-institutional coordination: Structure deals across the Broad, MIT, Harvard, affiliated hospitals, and HHMI, presenting a unified institutional interface while navigating divergent IP policies, co-ownership structures, and governance requirements. Consortium design: Designed governance, IP frameworks, and decision rights for multi-party research consortia involving pharma, biotech, academic, and funder participants.
Led BD and IP strategy across 100+ discovery and translational programs at an academic medical center. Hired, directed, and mentored junior BD staff. Structured complex multi-party and in-licensing agreements. Supported 8 faculty spinouts including Larkspur Biosciences (multi-institutional formation across 5 academic centers, novel equity structure, $35M raised, now Phase I). Served as principal liaison for Weill Cornell Medicine-Qatar, coordinating international research programs and partnerships.
Portfolio oversight of 300+ technologies across multiple schools. Hired and managed BD and technology assessment team members. Designed commercialization pathways and prioritization frameworks for discovery-stage research. Supported company formations including Katmai Pharmaceuticals (CNS-penetrant EGFR inhibitor, now Phase Ib for glioblastoma via Erasca partnership). Served on portfolio company boards as institutional representative. Co-created UCLA Life Science Innovation Day (now LA BEST), 700+ attendees from 150+ organizations.
Built a 25-person global innovation unit from scratch ($4.5M annual budget). Established evaluation frameworks, pipeline processes, and operating cadence for an internal venture portfolio. Recruited and led 20 internal venture teams across 6 countries in strategic fields including synthetic biology, bioprinting, and bioelectronics. Multiple ventures adopted by Merck and commercialized (M-Trust platform, bioprinting materials).